”Infections related to Antibiotic Resistent Bacteria (ARB) causes worldwide around 500,000 deaths yearly. This is an increasing threat and year 2050 it´s calculated that 10 million people will die in infections caused by ARB. Sepsis is defined as a life-threatening organ dysfunction due to a dysregulated host response to infection. It is a common disease with a high mortality rate. The cornerstone of treatment today is broad-spectrum antibiotics, but increasing resistance challenges the usage. A new technology, with a completely different approach, could be a valuable contribution in the future treatment”
A gamechanging technology to treat sepsis
Solution
The SangAsept-system allows for a mild treatment of the patient’s blood using active oxygen.
Read MoreSlows down and controls the infection
In this process, the blood temperature is initially lowered, and the blood is treated with a gas mixture of oxygen and ozone. The blood is then separated from excess gas, followed by a reheated step before being reintroduced into the patient.
Due to its immediate effect, SangAsept provides medical staff with a new method that can save lives and increase healthcare efficiency. Additionally, as SangAsept is a medical device rather than a pharmaceutical product, it can reduce the project’s development time and risk profile.
The primary focus of SangAsept is to treat the patient’s blood, thereby slowing down infections. The treatment effects are immediate, and it only affects the blood that passes through the system.
This allows medical staff to “dose” the treatment over time, giving them 100% control over the process. SangAsept somewhat resembles a dialysis machine, where blood is treated extracorporeally and then returned to the patient.